Whole genome characterization of non-tissue culture adapted HRSV strains in severely infected children

Virology Journal

Richard J Sugrue³  Eric AF Simões¹  Martin L Hibberd⁴  Laxmi Ravi Iyer³  Rajni Kumaria² 

[1] University of Colorado, Denver and The Division of Infectious Diseases, The Children's Hospital, 13123 East 16th Avenue, Aurora, CO 80045, USA;Singapore-MIT Alliance for Research and Technology, Centre for Life Sciences, #05-06M, 28 Medical Drive, 117456, Singapore;Division of Molecular and Cell biology, School of Biological Sciences, Nanyang Technological University, 60 Nanyang Drive, 639798, Singapore;Genome Institute of Singapore, #02-01, Genome Building, 60 Biopolis Street, 138672, Singapore

关键词: Protein analysis;    Phylogenetic analysis;    Whole genome sequence;    HRSV A type severe clinical strains;    Human respiratory syncytial virus;   

Others  :  1156396
DOI  :  10.1186/1743-422X-8-372

 received in 2011-04-22, accepted in 2011-07-28,  发布年份 2011

【 摘 要 】

Background

Human respiratory syncytial virus (HRSV) is the most important virus causing lower respiratory infection in young children. The complete genetic characterization of RSV clinical strains is a prerequisite for understanding HRSV infection in the clinical context. Current information about the genetic structure of the HRSV genome has largely been obtained using tissue culture adapted viruses. During tissue culture adaptation genetic changes can be introduced into the virus genome, which may obscure subtle variations in the genetic structure of different RSV strains.

Methods

In this study we describe a novel Sanger sequencing strategy which allowed the complete genetic characterisation of 14 clinical HRSV strains. The viruses were sequenced directly in the nasal washes of severely hospitalized children, and without prior passage of the viruses in tissue culture.

Results

The analysis of nucleotide sequences suggested that vRNA length is a variable factor among primary strains, while the phylogenetic analysis suggests selective pressure for change. The G gene showed the greatest sequence variation (2-6.4%), while small hydrophobic protein and matrix genes were completely conserved across all clinical strains studied. A number of sequence changes in the F, L, M2-1 and M2-2 genes were observed that have not been described in laboratory isolates. The gene junction regions showed more sequence variability, and in particular the intergenic regions showed a highest level of sequence variation. Although the clinical strains grew slower than the HRSVA2 virus isolate in tissue culture, the HRSVA2 isolate and clinical strains formed similar virus structures such as virus filaments and inclusion bodies in infected cells; supporting the clinical relevance of these virus structures.

Conclusion

This is the first report to describe the complete genetic characterization of HRSV clinical strains that have been sequenced directly from clinical material. The presence of novel substitutions and deletions in the vRNA of clinical strains emphasize the importance of genomic characterization of non-tissue culture adapted primary strains.

【 授权许可】

   
2011 Kumaria et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]WHO Initiative for Vaccine Research: Acute Respiratory Infections (Update September 2009). [http://www.who.int/vaccine_research/diseases/ari/en/index.html] webcite Accessed 13 August 2010
• [2]Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O'Brien KL, Roca A, Wright PF, Bruce N, Chandran A, Theodoratou E, Sutanto A, Sedyaningsih ER, Ngama M, Munywoki PK, Simões EAF, Martin IR, Weber W, Campbell H: Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: systematic review and meta-analysis. Lancet 2010, 375(9725):1545-1555.
• [3]Collins PL, Hill MG, Cristina J, Grosfeld H: Transcription elongation factor of respiratory syncytial virus, a nonsegmented negative-strand RNA virus. Proc Natl Acad Sci USA 1996, 93:81-85.
• [4]Grosfeld H, Hill MG, Collins PL: RNA replication by respiratory syncytial virus (RSV) is directed by the N, P, and L proteins; transcription also occurs under these conditions but requires RSV superinfection for efficient synthesis of full-length mRNA. J Virol 1995, 69:5677-5686.
• [5]Yu Q, Hardy RW, Wertz GW: Functional cDNA clones of the human respiratory syncytial (RS) virus N, P, and L proteins support replication of RS virus genomic RNA analogs and define minimal trans-acting requirements for RNA replication. J Virol 1995, 69:2412-2419.
• [6]Jin H, Cheng X, Zhou HZ, Li S, Seddiqui A: Respiratory syncytial virus that lacks open reading frame 2 of the M2 gene (M2-2) has altered growth characteristics and is attenuated in rodents. J Virol 2000, 74(1):74-82.
• [7]Bermingham A, Collins PL: The M2-2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA replication and transcription. Proc Natl Acad Sci USA 1999, 96:11259-11264.
• [8]Fearns R, Collins PL: Role of the M2-1 transcription antitermination protein of respiratory syncytial virus in sequential transcription. J Virol 1999, 73:5852-5864.
• [9]Ghildyal R, Mills J, Murray M, Vardaxis N, Meanger J: Respiratory syncytial virus matrix protein associates with nucleocapsids in infected cells. J Gen Virol 2002, 83:753-757.
• [10]Hardy RW, Wertz GW: The product of the respiratory syncytial virus M2 gene ORF1 enhances read-through of intergenic junctions during viral transcription. J Virol 1998, 72:520-526.
• [11]Levine SR, Klaiber-Franco , Paradiso PR: Demonstration that glycoprotein G is the attachment protein of respiratory syncytial virus. J Gen Virol 1987, 68:2521-2524.
• [12]Scheid A, Choppin PW: Two disulfide-linked polypeptide chains constitute the active F protein of paramyxoviruses. Virology 1977, 80:54-66.
• [13]Schlender J, Bossert B, Buchholz U, Conzelmann KK: Bovine respiratory syncytial virus nonstructural proteins NS1 and NS2 cooperatively antagonize alpha/beta interferon-induced antiviral response. J Virol 2000, 74:8234-8242.
• [14]Mufson MA, Belshe RB, Orvell C, Norrby E: Two distinct subtypes of human respiratory syncytial virus. J Gen Virol 1985, 66:2111-2124.
• [15]Cane PA, Matthews D, Pringle C: Identification of variable domains of the attachment G protein of subgroup A respiratory syncytial viruses. J Gen Virol 1991, 72:2091-2096.
• [16]Choi EH, Lee HJ: Genetic diversity and molecular epidemiology of the G protein of subgroups A and B of respiratory syncytial viruses isolated over 9 consecutive epidemics in Korea. J Infect Dis 2000, 181:1547-1556.
• [17]Martinello RA, Chen M D, Weibel C, Kahn JS: Correlation between respiratory syncytial virus genotype and severity of illness. J Infect Dis 2002, 186:839-842.
• [18]Rafiefard F, Johansson B, Tecle T, Orvell C: Molecular epidemiology of respiratory syncytial virus (RSV) of group A in Stockholm, Sweden, between 1965 and 2003. Virus Res 2004, 105:137-145.
• [19]da Silva LHA, Spilki FR, Riccetto AGL, de Almeida RS, Baracat ECE, Arns CW: Genetic Variability in the G protein gene of human respiratory syncytial virus isolated from the Campinas metropolitan region, Brazil. J Med Virol 2008, 80:1653-1660.
• [20]Peret TC, Hall CB, Schnabel KC, Golub JA, Anderson JA: Circulation patterns of genetically distinct group A and B strains of human respiratory syncytial virus in a community. J Gen Virol 1998, 79:2221-2229.
• [21]Cane PA: Molecular epidemiology of respiratory syncytial virus. Rev Med Virol 2001, 11:103-116.
• [22]Montieri S, Puzelli S, Ciccozzi M, Calzoletti L, Di Martino A, Milia MG, Rossi A, Piro F, Rezza G, Donatelli I: Amino acid changes in the attachment G glycoprotein of human respiratory syncytial viruses (Subgroup A) isolated in Italy over several epidemics (1997-2006). J Med Virol 2007, 79:1935-1942.
• [23]Gilca R, De Serres G, Tremblay M, Vachon ML, Leblanc E, Bergeron MG, Dery P, Boivin G: Distribution and Clinical Impact of Human Respiratory Syncytial Virus Genotypes in Hospitalized Children. J Infect Dis 2006, 193:54-58.
• [24]Kaplan NM, Dove W, Abd-Eldayem SA, Abu-Zeid AF, Shamoon HE, Hart CA: Molecular epidemiology and disease severity of respiratory syncytial virus in relation to other potential pathogens in children hospitalized with acute respiratory infection in Jordan. J Med Virol 2008, 80:168-174.
• [25]Collins PL, Olmsted RA, Spriggs MK, Johnson PR, Buckler-White AJ: Gene overlap and site-specific attenuation of transcription of the viral polymerase L gene of human respiratory syncytial virus. Proc Natl Acad Sci USA 1987, 84(15):5134-5138.
• [26]Lo MS, Brazas RM, Holtzman MJ: Human respiratory syncytial virus strain ATCC VR-26, complete genome. [http://www.ncbi.nlm.nih.gov/nuccore/60549163] webcite 2009. Accessed 13 January 2009
• [27]Mink MA, Stec DS, Collins PL: Nucleotide sequences of the 3' leader and 5' trailer regions of human respiratory syncytial virus genomic RNA. Virology 1991, 185(2):615-624.
• [28]Moore ML, Chi MH, Luongo C, Lukacs NW, Polosukhin VV, Huckabee MM, Newcomb DC, Buchholz UJ, Crowe JE, Goleniewska K, Williams JV, Collins PL, Peebles S: A chimeric A2 strain of respiratory syncytial virus (RSV) with the fusion protein of RSV strain line 19 exhibits enhanced viral load, mucus, and airway dysfunction. J Virol 2009, 83(9):4185-4194.
• [29]Stec DS, Hill MG, Collins PL: Sequence analysis of the polymerase L gene of human respiratory syncytial virus and predicted phylogeny of nonsegmented negative-strand viruses. Virology 1991, 183(1):273-287.
• [30]Tolley KP, Marriott AC, Simpson A, Plows D J, Mattews DA, Longhurst SJ, Evans JE, Johnson JL, Cane PA, Randolph VB, Easton AJ, Pringle CR: Identification of mutations contributing to the reduced virulence of a modified strain of respiratory syncytial virus. Vaccine 1996, 14:1637-1646.
• [31]Tamura K, Nei M, Kumar S: Prospects for inferring very large phylogenies by using the neighbor-joining method. Proc Natl Acad Sci USA 2004, 101:11030-11035.
• [32]Felsenstein J: Confidence limits on phylogenies: An approach using the bootstrap. Evolution 1985, 39:783-791.
• [33]Tamura K, Dudley J, Nei M, Kumar S: MEGA4: Molecular evolutionary genetics analysis (MEGA) software version 4.0. Mol Biol Evol 2007, 24:596-1599.
• [34]Brown G, Aitken J, Rixon HW, Sugrue RJ: Caveolin-1 is incorporated into mature respiratory syncytial virus particles during virus assembly on the surface of virus-infected cells. J Gen Virol 2002, 83:611-621.
• [35]Botosso VF, Zanotto PM, Ueda M, Arruda E, Gilio AE, Vieira SE, Stewien KE, Peret TCT, Jamal LF, Pardini MIMC, Pinho JRR, Massad E, Sant'Anna OA, Holmes EC, Durigon EL, VGDN Consortium: Positive selection results in frequent reversible amino acid replacements in the G protein gene of human respiratory syncytial virus. [http://www.plospathogens.org] webcitePLoS Pathogens 2009, (1):e1000254.
• [36]Garcia O, Martin M, Dopazo J, Arbiza J, Frabasile S, Russi J, Hortal M, Perez-Brena P, Martinez I, Garcia-Barreno B, Melero JA: Evolutionary pattern of human respiratory syncytial virus subgroup A: co circulating lineages and correlation of genetic and antigenic changes in the G glycoprotein. J Virol 1994, 68:5448-5459.
• [37]Martinez I, Dopazo J, Melero JA: Antigenic structure of the human respiratory syncytial virus G glycoprotein and relevance of hypermutation events for the generation of antigenic variants. J Gen Virol 1997, 78:2419-2429.
• [38]Rueda P, Delgado T, Portela A, Melero JA, Garcia-Barreno B: Premature stop codons in the G glycoprotein of human respiratory syncytial viruses resistant to neutralization by monoclonal antibodies. J Virol 1991, 65(6):3374-3378.
• [39]Hallak LK, Spillmann D, Collins PL, Peeples ME: Glycosaminoglycan sulfation requirements for respiratory syncytial virus infection. J Virol 2000, 74(22):10508-10513.
• [40]Tripp RA, Jones LP, Haynes LM, Zheng HQ, Murphy PM, Anderson LJ: CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat Immunol 2001, 2:732-738.
• [41]Steven A, Feldman R, Hendry M, Beeler JA: Identification of a linear heparin binding domain for human respiratory syncytial virus attachment glycoprotein G. J Virol 1999, 73(8):6610-6617.
• [42]Sugrue RJ, Brown C, Brown G, Aitken J, Rixon HW: Furin cleavage of the respiratory syncytial virus fusion protein is not a requirement for its transport to the surface of virus-infected cells. J Gen Virol 2001, 82:1375-1386.
• [43]Zimmer G, Rohn M, McGregor GP, Schemann M, Conzelmann KK, Herrler G: Virokinin, a bioactive peptide of the tachykinin family, is released from the fusion protein of bovine respiratory syncytial virus. J Biol Chem 2003, 278(47):46854-46861.
• [44]Agenbach E, Tiemessen CT, Venter M: Amino acid variation within the fusion protein of respiratory syncytial virus subtype A and B strains during annual epidemics in South Africa. Virus Genes 2005, 30(2):267-278.
• [45]Brandenburg AH, De-Waal L, Timmerman HH, Hoogerhout P, De-Swart RL, Osterhaus AD: HLA class I-restricted cytotoxic T-cell epitopes of the respiratory syncytial virus fusion protein. J Virol 2000, 74:10240-10244.
• [46]IMPACT-RSV Study Group: Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998, 102:531-537.
• [47]Zhao X, Chen FP, Sullender WM: Respiratory syncytial virus escape mutant derived in vitro resists palivizumab prophylaxis in cotton rats. Virology 2004, 318:608-612.
• [48]Zhao X, Liu E, Chen FP, Sullender WM: In Vitro and In Vivo Fitness of Respiratory Syncytial Virus Monoclonal Antibody Escape Mutants. J Virol 2006, 80(23):11651-11657.
• [49]Cardenas S, Auais A, Piedimonte G: Palivizumab in the prophylaxis of respiratory syncytial virus infection. Expert Rev Anti Infect Ther 2005, 3:719-726.
• [50]Everitt DE, Davis CB, Thompson K, DiCicco R, Ilson B, Demuth SG, Herzyk DJ, Jorkasky DK: The pharmacokinetics, antigenicity, and fusion-inhibition activity of RSHZ19, a humanized monoclonal antibody to respiratory syncytial virus, in healthy volunteers. J Infect Dis 1996, 174:463-469.
• [51]Chen MD, Vazquez M, Buonocore L, Kahn JS: Conservation of the respiratory syncytial virus SH gene. J InfecT Dis 2000, 182:1228-1233.
• [52]Bukreyev A, Whitehead SS, Murphy BR, Collins PL: Recombinant respiratory syncytial virus from which the entire SH gene has been deleted grows efficiently in cell culture and exhibits site-specific attenuation in the respiratory tract of the mouse. J Virol 1997, 71(12):8973-8982.
• [53]Ferron F, Longhi S, Henrissat B, Canard B: Viral RNA polymerases - a predicted 29-O-ribose methyltransferase domain shared by all Mononegavirales. Trends Biochem Sci 2002, 27:222-224.
• [54]Poch O, Blumberg BM, Bougueleret L, Tordo N: Sequence comparison of five polymerases (L proteins) of unsegmented negative-strand RNA viruses: theoretical assignment of functional domains. J Gen Virol 1990, 71:1153-1162.
• [55]Hardy RW, Wertz GW: The Cys(3)-His(1) motif of the respiratory syncytial virus M2-1 protein is essential for protein function. J Virol 2000, 74(13):5880-5885.
• [56]Tang RS, Nguyen N, Cheng X, Jin H: Requirement of cysteines and length of the human respiratory syncytial virus M2-1 protein for protein function and virus viability. J Virol 75(23):11328-11335.
• [57]Ahmadian G, Chambers P, Easton AJ: Detection and characterization of proteins encoded by the second ORF of the M2 gene of pneumoviruses. J Gen Virol 1999, 80:2011-2016.
• [58]Cheng X, Park HJ, Zhou H, Jin H: Over expression of the M2-2 Protein of Respiratory Syncytial Virus Inhibits Viral Replication. J Virol 2005, 79(22):13943-13952.
• [59]Moudy RM, Harmon SB, Sullender WM, Wertz GW: Variations in transcription termination signals of Human respiratory syncytial virus clinical isolates affect gene expression. Virology 2003, 313:250-260.
• [60]Elliott J, Lynch OT, Suessmuth Y, Qian P, Boyd CR, Burrows JM, Buick R, Stevenson NJ, Touzelet O, Gadina M, Power UF, Johnston JA: Respiratory syncytial virus NS1 protein degrades STAT2 by using the Elongin-Cullin E3 ligase. J Virol 2007, 81(7):3428-3436.
• [61]Zhang W, Yang H, Kong X, Mohapatra S, Juan-Vergara HS, Hellermann G, Behera S, Singam R, Lockey RF, Mohapatra SS: Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene. Nature Medicine 2004, 11:56-62.
• [62]McGivern DR, Collins PL, Fearns R: Identification of internal sequences in 3' leader region of human respiratory syncytial virus that enhance transcription and confer replication processivity. Virology 2005, 79(4):2449-2460.
• [63]Fearns R, Peeples ME, Collins PL: Mapping the Transcription and Replication Promoters of Respiratory Syncytial Virus. J Virol 2002, 76(4):1663-1672.
• [64]Cowton VM, Fearns R: Evidence that the respiratory syncytial virus polymerase is recruited to nucleotides 1 to 11 at the 3' end of the nucleocapsid and can scan to access internal signals. J Virol 2005, 79:11311-11322.
• [65]Kuo L, Fearns R, Collins PL: Analysis of the gene start and gene end signals of human respiratory syncytial virus: Quasi-templated initiation at position 1 of the encoded mRNA. J Virol 1997, 71(7):4944-4953.
• [66]Harmon SB, Megaw AG, Wertz GW: RNA sequences involved in transcriptional termination of respiratory syncytial virus. J Virol 2001, 75(1):36-44.
• [67]Peeples M, Collins PL: Mutations in the trailer region of a respiratory syncytial virus minigenome which limit RNA replication to one Step. J Virol 2000, 74(1):146-155.
• [68]Moudy RM, Sullender WM, Wertz GW: Variations in intergenic region sequences of Human respiratory syncytial virus clinical isolates: analysis of effects on transcriptional regulation. Virology 2004, 327:121-133.
• [69]Villenave R, O'Donoghue D, Thavagnanam S, Touzelet O, Skibinski G, Heaney LG, McKaigue JP, Coyle PV, Shields MD, Power UF: Differential cytopathogenesis of respiratory syncytial virus prototypic and clinical isolates in primary pediatric bronchial epithelial cells. Virology Journal 2011, 8:43. BioMed Central Full Text
• [70]Radhakrishnan A, Yeo D, Brown G, Myaing MZ, Iyer LR, Fleck R, Tan BH, Aitken J, Sanmun D, Tang K, et al.: Protein analysis of purified respiratory syncytial virus particles reveals an important role for heat shock protein 90 in virus particle assembly. Mol Cell Proteomics 2010, 9(9):1829-48.